BLCO
Bausch + Lomb Corporation · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth -13.3% ·
share flow +10.3% ·
net new positions -15.4%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 46 | +1 | 24.68M | $408.72M | +5 | −4 |
| Q1 2026 | 45 | -1 | 23.90M | $380.01M | +5 | −6 |
| Q4 2025 | 46 | +1 | 23.58M | $402.66M | +2 | −1 |
| Q3 2025 | 13 | -2 | 16.68M | $251.34M | — | −2 |
| Q2 2025 | 12 | -2 | 14.01M | $182.32M | +1 | −3 |
| Q1 2025 | 12 | +1 | 9.66M | $140.02M | +2 | −1 |
| Q4 2024 | 11 | +3 | 8.82M | $159.20M | +3 | — |
| Q3 2024 | 7 | -1 | 7.17M | $138.23M | +1 | −2 |
| Q2 2024 | 8 | — | 5.22M | $75.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 3.50M | 0.0% | $52.74M | 0.6% | Held | 6 | SEC ↗ |
| 2 | Oaktree Capital Management ✦ | 3.25M | +28.7% | $48.91M | 1.0% | ▲ Add | 2 | SEC ↗ |
| 3 | D. E. Shaw & Co. ✦ | 2.61M | 0.0% | $39.29M | 0.0% | Held | 6 | SEC ↗ |
| 4 | Fidelity (FMR) ✦ | 1.56M | +102.1% | $23.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | Glenview Capital ✦ | 1.55M | 0.0% | $23.42M | 0.6% | Held | 3 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 1.24M | -1.0% | $18.64M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 1.24M | -1.0% | $18.64M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 1.06M | -4.5% | $16.00M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 752.13K | — | $11.33M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Morgan Stanley ✦ | 752.13K | — | $11.33M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 752.13K | — | $11.33M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 752.13K | — | $11.33M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 702.22K | +138.6% | $10.58M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Goldman Sachs Group ✦ | 350.94K | — | $5.29M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | GAMCO Investors ✦ | 85.00K | -0.6% | $1.28M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | BlackRock ✦ (passive) | 22.67K | -4.0% | $341,622 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | BlackRock ✦ (passive) | 22.67K | -4.0% | $341,622 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | JPMorgan Chase ✦ | 166 | — | $2,502 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | JPMorgan Chase ✦ | 166 | — | $2,502 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Millennium Management | $3.58M | was 0.0% |
| State Street Global Advisors | $243,287 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 95 holders, 37.97M shares, $580.19M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 52.90K sh · $887,662
Director · 6.06K sh · $100,458
Director · 12.50K sh · $206,250
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology